Catalent, Inc. (CTLT)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:02PM EDT
After hours:
| Previous close | 45.78 |
| Open | 45.64 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's range | 45.21 - 46.05 |
| 52-week range | 31.45 - 81.72 |
| Volume | |
| Avg. volume | 2,266,067 |
| Market cap | 8.24B |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.29 |
| Earnings date | 30 Oct 2023 - 03 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.29 |
ZacksCatalent (CTLT) Down 6.5% Since Last Earnings Report: Can It Rebound?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
- Business Wire
Catalent Appoints David McErlane as Biologics Segment Leader
SOMERSET, N.J., September 18, 2023--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023.
© 2023 Yahoo. All rights reserved.
